Related Experiment Video
Updated: Feb 2, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
The US Biosimilar Market: Stunted Growth and Possible Reforms
Ameet Sarpatwari1, Rachel Barenie1, Gregory Curfman1
1Program On Regulation, Therapeutics, And Law (PORTAL), Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
In 2010, Congress created an abbreviated application pathway for biosimilars, versions of approved biologics made by different manufacturers. However, as of November 1, 2018, the US Food and Drug Administration (FDA) had approved only 13 biosimilars under this pathway, of which just 6 were available for patients to use. We review the history of US regulation of biologics and identify manufacturing, regulatory, and marketing issues that have limited biosimilar market entry and uptake, concluding with recommendations for reform.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Population Growth
Meristems and Plant Growth
Exponential Growth
Relationship Growth
Primary and Secondary Growth in Roots and Shoots

